Related references
Note: Only part of the references are listed.Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2
Yejin Jang et al.
SCIENTIFIC REPORTS (2021)
Use of Protein Pegylation to Prolong the Antiviral Effect of IFN Against FMDV
Fayna Diaz-San Segundo et al.
FRONTIERS IN MICROBIOLOGY (2021)
A Vaccine Strain of the A/ASIA/Sea-97 Lineage of Foot-and-Mouth Disease Virus with a Single Amino Acid Substitution in the P1 Region That Is Adapted to Suspension Culture Provides High Immunogenicity
Ji-Hyeon Hwang et al.
VACCINES (2021)
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
Sachin Bhagchandani et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model
Yunlong Hu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice
Shannon M. Miller et al.
FRONTIERS IN IMMUNOLOGY (2020)
Enhanced efficacy of a multi-epitope vaccine for type A and O foot-and-mouth disease virus by fusing multiple epitopes with Mycobacterium tuberculosis heparin-binding hemagglutinin (HBHA), a novel TLR4 agonist
Yao Lei et al.
MOLECULAR IMMUNOLOGY (2020)
Chimeric vaccine strain of type O foot-and-mouth disease elicits a strong immune response in pigs against ME-SA and SEA topotypes
Mi-Kyeong Ko et al.
VETERINARY MICROBIOLOGY (2019)
Mincle and STING-Stimulating Adjuvants Elicit Robust Cellular Immunity and Drive Long-Lasting Memory Responses in a Foot-and-Mouth Disease Vaccine
Min Ja Lee et al.
FRONTIERS IN IMMUNOLOGY (2019)
Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model
An-Ting Liou et al.
JOURNAL OF BIOMEDICAL SCIENCE (2019)
TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation
Daniel Enosi Tuipulotu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
GS-9620 inhibits enterovirus 71 replication mainly through the NF-κB and PI3K-AKT signaling pathways
Qian Zhang et al.
ANTIVIRAL RESEARCH (2018)
Antiviral activity of porcine interferon delta 8 against foot-and-mouth disease virus in vitro
Shi-fang Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B
Harry L. A. Janssen et al.
JOURNAL OF HEPATOLOGY (2018)
Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment
K. Agarwal et al.
JOURNAL OF VIRAL HEPATITIS (2018)
Synthetic RNA derived from the foot-and-mouth disease virus genome elicits antiviral responses in bovine and porcine cells through IRF3 activation
Miguel Rodriguez Pulido et al.
VETERINARY MICROBIOLOGY (2018)
Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial
Stephane Pillet et al.
NPJ VACCINES (2018)
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
Rhea N. Coler et al.
NPJ VACCINES (2018)
TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
Rujuta A. Bam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Swine IRF3/IRF7 attenuates inflammatory responses through TLR4 signaling pathway
Pei-Ge Chen et al.
ONCOTARGET (2017)
Antiviral activity of ovine interferon tau 4 against foot-and-mouth disease virus
Jayaramaiah Usharani et al.
ANTIVIRAL RESEARCH (2017)
Effects of porcine MyD88 knockdown on the expression of TLR4 pathway-related genes and proinflammatory cytokines
Chaohui Dai et al.
BIOSCIENCE REPORTS (2016)
Constitutively Active IRF7/IRF3 Fusion Protein Completely Protects Swine against Foot-and-Mouth Disease
Lisbeth Ramirez-Carvajal et al.
JOURNAL OF VIROLOGY (2016)
Complexities in Isolation and Purification of Multiple Viruses from Mixed Viral Infections: Viral Interference, Persistence and Exclusion
Naveen Kumar et al.
PLOS ONE (2016)
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
Edward J. Gane et al.
JOURNAL OF HEPATOLOGY (2015)
Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B
Stephan Menne et al.
JOURNAL OF HEPATOLOGY (2015)
Robust Protection against Highly Virulent Foot-and-Mouth Disease Virus in Swine by Combination Treatment with Recombinant Adenoviruses Expressing Porcine Alpha and Gamma Interferons and Multiple Small Interfering RNAs
Su-Mi Kim et al.
JOURNAL OF VIROLOGY (2015)
Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
Rachel Lubong Sabado et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C
Eric Lawitz et al.
ANTIVIRAL THERAPY (2015)
The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes
Lakshmi Ganapathi et al.
PLOS ONE (2015)
A recombinant adenovirus bicistronically expressing porcine interferon-α and interferon-γ enhances antiviral effects against foot-and-mouth disease virus
Su-Mi Kim et al.
ANTIVIRAL RESEARCH (2014)
Resiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine
Chun-Xue Zhou et al.
BMC VETERINARY RESEARCH (2014)
Pharmacokinetic and Pharmacodynamic Properties of GS-9620, a Novel Toll-Like Receptor 7 Agonist, Demonstrate Interferon-Stimulated Gene Induction without Detectable Serum Interferon at Low Oral Doses
Abigail Fosdick et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist
Uri Lopatin et al.
ANTIVIRAL THERAPY (2013)
BASIC AND TRANSLATIONAL-LIVER
Robert E. Lanford et al.
GASTROENTEROLOGY (2013)
Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion
Jurjen Tel et al.
JOURNAL OF IMMUNOLOGY (2013)
Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-α and antiviral agents
Su-Mi Kim et al.
ANTIVIRAL RESEARCH (2012)
Novel Antiviral Therapeutics to Control Foot-and-Mouth Disease
Camila C. Dias et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2012)
Selection and characterisation of guanidine-resistant mutants of human enterovirus 71
Sara Sadeghipour et al.
VIRUS RESEARCH (2012)
Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
Rhea N. Coler et al.
PLOS ONE (2011)
Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus
Su-Mi Kim et al.
ANTIVIRAL RESEARCH (2010)
Structure-Activity Relationships in Human Toll-Like Receptor 7-Active Imidazoquinoline Analogues
Nikunj M. Shukla et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Interferon-Induced Protection against Foot-and-Mouth Disease Virus Infection Correlates with Enhanced Tissue-Specific Innate Immune Cell Infiltration and Interferon-Stimulated Gene Expression
Fayna Diaz-San Segundo et al.
JOURNAL OF VIROLOGY (2010)
CXCL10 Inhibits Viral Replication Through Recruitment of Natural Killer Cells in Coxsackievirus B3-Induced Myocarditis
Ji Yuan et al.
CIRCULATION RESEARCH (2009)
Activation of Porcine Natural Killer Cells and Lysis of Foot-and-Mouth Disease Virus Infected Cells
Felix N. Toka et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2009)
Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications
C. Guiducci et al.
JOURNAL OF INTERNAL MEDICINE (2009)
Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons
Mauro Pires Moraes et al.
JOURNAL OF VIROLOGY (2007)
Type I inteferon gene induction by the interferon regulatory factor family of transcription factors
Kenya Honda et al.
IMMUNITY (2006)
Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production
JF Gerster et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
TLR signalling and activation of IRFs: revisiting old friends from the NF-kappa B pathway
PN Moynagh
TRENDS IN IMMUNOLOGY (2005)
Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis
A Airaksinen et al.
VIROLOGY (2003)
The pathogenesis and diagnosis of foot-and-mouth disease
S Alexandersen et al.
JOURNAL OF COMPARATIVE PATHOLOGY (2003)
Share Paper
